Description  Claims  Drawing  Cited references 

US61568110A   [0001] 
US61628999A   [0001] 
US61532534A   [0001] 
US61530873A   [0001] 
WO2008154382A   [0008] 
US2009048156A   [0008] 
US4328245A   [0101] 
US4409239A   [0101] 
US4410545A   [0101] 
US6350458B   [0104] 

Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing in aromatase inhibitor therapy   [0008] 
Functional activation of the estrogen receptor and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumours to letrozole   [0008] 
Remington: The Science and Practice of Pharmacy   [0040] 
Handbook of Pharmaceutical Excipients   [0040] 
Handbook of Pharmaceutical Additives   [0040] 
Pharmaceutical Preformulation and Formulation   [0040] 
J. Biol. Chem.   [0069] 
Metabolism   [0070] 
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer   [0079] 
Functional activation of the estrogen receptor-a and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole   [0080] 
HDAC Inhibitor Entinostat Restores Responsiveness of Letrozole Resistant MCF-7Ca Xenografts to AIs through Modulation of Her-2   [0080] 
Journal of Clinical Oncology   [0087] 
Design issues of randomized Phase 2 trials and a proposal for Phase 2 screening trials   [0137] 
Clinical trial designs for cytostatic agents: are new approaches needed?   [0137]